Fig. 2
Functional activity of intrinsic PD-1 in TC cells. a. DNA synthesis of 8505c and TPC-1 cells transiently transfected with pFLAG PD-1 or the relative empty vector (pFLAG), or treated or not with soluble PD-L1 (sPD-L1–1 μg/ml) assessed by BrdU incorporation. Data are presented as mean ± SD of 5 independent experiments. b. DNA synthesis of 8505c and TPC-1 cells treated with siRNA targeting PD-1 (siPD-1 – 100 nM) or the relative control (siCTR – 100 nM) for 48 h or treated with Nivolumab (Nivo - 10 μg/ml) or control IgG4 (10 μg/ml) for 24 h assessed by BrdU incorporation. Data are presented as mean ± SD of 5 independent experiments. c. Percent of migrated cells over control (empty vector transfected – pCMV3) of stably transfected 8505c PD-1 cells versus 10% FBS, or of 8505c cells treated with Nivolumab (Nivo - 10 μg/ml) or control IgG4 (10 μg/ml) toward sPD-L1 (1 μg/ml) or medium alone (NT). Data are presented as mean ± SD of 5 independent experiments. * P < 0.05 compared to the relative untreated cells. § P < 0.05 compared to sPD-L1 alone